Diagnostic Center | June 15, 2024
Sun Pharma and Moebius Medical present Phase 2b study on MM-II
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Accelerating sustainability in Indian pharma industry
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Subscribe To Our Newsletter & Stay Updated
